ArticleThe Journal of experimental medicine2018

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

Michela Serresi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.